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Abstract 
To examine how heat shock transcription factor 1 (HSF1) protects against maladaptive 
hypertrophy during pressure overload, we subjected HSF1 transgenic (TG), knockout 
(KO) and wild type (WT) mice to a constriction of transverse aorta (TAC), and found that 
cardiac hypertrophy, functions and angiogenesis were well preserved in TG mice but 
were decreased in KO mice compared to WT ones at 4 weeks, which was related to 
HIF-1 and p53 expression. Inhibition of angiogenesis suppressed cardiac adaptation in 
TG mice while overexpression of angiogenesis factors improved maladaptive 
hypertrophy in KO mice. In vitro formation of vasculatures by microvascular endothelial 
cells was higher in TG mice but lower in KO mice than in WT ones. A siRNA of p53 but 
not a HIF-1 gene significantly reversed maladaptive hypertrophy in KO mice whereas a 
siRNA of HIF-1 but not a p53 gene induced maladaptive hypertrophy in TG mice. Heart 
microRNA analysis showed that miR-378 and miR-379 were differently changed among 
the three mice after TAC, and miR-378 or siRNA of miR-379 could maintain cardiac 
adaptation in WT mice. These results indicate that HSF1 preserves cardiac adaptation 
during pressure overload through p53-HIF-1-associated angiogenesis, which is controlled 
by miR-378 and miR-379. 
Introduction 
Congestive heart failure is an end-stage of various heart diseases, which still accounts the 
reason for the high morbidity and mortality in many countries. However, the fundamental 
mechanisms of the development of heart failure have not yet been fully understood, 
thereby the potential strategies for the treatment of heart failure still need to be 
developed. 
Heart failure is usually developed from a variety of heart diseases including 
cardiac hypertrophy 1. Cardiac hypertrophy is the compensation for pressure overload 2. 
Also, it is often an adaptation to exercises 3. Although pressure overload-induced cardiac 
hypertrophy may have beneficial effects at the beginning to maintain cardiac function, it 
would ultimately develop to heart failure at chronic stage 4. However, exercise-induced 
cardiac hypertrophy could maintain the adaptive state and normal function without 
progression to heart failure 3, 5. Recently, we have reported that heat shock transcription 
factor 1 (HSF1), an important transcription factor for heat shock proteins and one of the 
highly conserved protective factor, plays a critical role in exercise-induced adaptive 
cardiac hypertrophy in mice 6. In the study, expression of HSF1 and its target molecule 
heat shock proteins was significantly upregulated in the heart by exercise but not by 
chronic pressure overload. HSF1 has protective roles against hypertrophy induced by 
chronic pressure overload in the HSF1 transgenic mice. Overexpression of HSF1 in the 
heart prevented cardiomyocyte death and myocardial fibrosis in response to sustained 
pressure overload, thereby preserved cardiac function, and decrease of expression of 
HSF1 in the heart impaired the adaptive response to exercise or acute pressure overload 
and thus caused cardiac dysfunction. On the other hand, it has been reported that 
transcription of HSPs by HSF1 may be directly activated by pressure overload in the 
heart in both in vitro and in vivo models, which plays an important role in myocardial 
protection against cardiac overload 7. It has also been reported that HSF1 activation and 
HSP72 gene transcriptional competence during simulated exercise are linked to elevated 
heart temperature and are not a direct function of increased cardiac workload 8. However, 
whether and how HSF1 could protect against the transition of an adaptive cardiac 
hypertrophy to heart failure during a permanent pressure overload is still unclear. 
Recently, we showed in our another study that cardiac angiogenesis induced by 
HIF-1 is crucially involved in the adaptive mechanism of cardiac hypertrophy and that 
impairment of cardiac angiogenesis by p53 accumulation induces transition of the 
adaptive cardiac hypertrophy to heart failure 9. These data collectively suggest that there 
is a relationship between HSF1-regulated protection of cardiac function and 
HIF-1/p53-related angiogenesis in myocardium. In the present study, using a permanent 
pressure overload model by constriction of the aorta (TAC) in the HSF1 transgenic (TG) 
or knockout (KO) mice and their littermate wild type (WT) mice, we demonstrated 
whether and how HSF1 preserves adaptation of the heart during a persistent cardiac 
workload. 
 
Results 
Overexpression of HSF1 enhanced cardiac hypertrophy and functions during 
pressure overload in mice 
To begin investigating the role of HSF1 as a cardiac protective factor during pressure 
overload, we performed the operation of TAC in the WT, HSF1-TG and -KO adult mice 
and observed the development of cardiac hypertrophy and changes in cardiac functions 
for 4 weeks. These mice were apparently healthy, and there were no significant 
differences in the body weight (BW), heart weight to BW ratio (HW/BW), or 
hemodynamic parameters, such as blood pressure (BP), heart rate (HR) and left ventricle 
(LV) end-diastolic pressure (LVEDP), among the three type mice before the TAC 6, 10 
(data not shown). After TAC, BP was elevated by 40~50 mmHg similarly in the three 
types of mice, which was persistent for 4 weeks. However, cardiac hypertrophy and 
functions analyzed by echocardiography, catheterization and histology were quite 
different among the three mice. After TAC, cardiac hypertrophy was more significantly 
formed in the TG mice (Fig. 1b) but less in the KO mice (Fig. 1c) than in the WT ones 
(Fig. 1a). Although cardiac function was well preserved in the TG mice for 4 weeks, it 
was significantly decreased at 4 weeks in the WT mice while at 2 weeks in the KO ones 
after TAC (Fig. 1d). On the other hand, intercellular collagen content in myocardium was 
less in the TG mice but more in the KO mice than in WT mice after TAC (Fig. 1a-c). 
These results suggested that HSF1 could enhance adaptive hypertrophy and preserve 
cardiac functions during a permanent pressure overload. 
 
Overexpression of HSF1 promoted cardiac angiogenesis after pressure overload 
We next asked whether the role of HSF1 is associated with an increase in angiogenesis in 
myocardium after pressure overload since angiogenesis is important for the development 
of cardiac hypertrophy 9. Immunohistochemical staining of myocardial sections with an 
anti factor VIII-related antigen (von Willebrand factor, vWF), which specifically 
expressed in endothelial cells, revealed that the densities of vWF-positive vasculatures 
were higher in the heart of TG mice but lower in the heart of KO mice than those in the 
heart of WT mice after TAC (Fig. 2a), consisting with the results of cardiac hypertrophy. 
Inhibition of angiogenesis with an inhibitor TNP-470, significantly suppressed 
TAC-induced cardiac hypertrophy in the TG mice (Fig. 2b), while improving of 
angiogenesis by introducing the VEGF with Ang-1 genes into the heart of KO mice could 
increase hypertrophy after TAC (Fig. 2c). These results indicated that the role of HSF1 in 
maintaining the adaptive cardiac hypertrophy during pressure overload is associated with 
angiogenesis. 
 
HSF1 induced reprogramming of expression of HIF-1 and p53 in the heart during 
pressure overload 
Since we have recently reported that HIF-1-regulated angiogenesis is important for the 
development of pressure overload-induced cardiac hypertrophy and that p53-induced 
inhibition of HIF-1 causes the transition from cardiac hypertrophy to heart failure 9. We 
therefore asked whether HSF1 might induce angiogenesis through regulation of HIF-1 
and p53 during pressure overload. There were no differences in expression of HIF-1 and 
p53 at basal condition before TAC (data not show). After TAC, consisting with our 
previous study 9, expression of HIF-1 in WT heart was increased at early phase and 
decreased from 2 weeks after TAC, and expression of p53 was unchanged at early stage 
but elevated from 2 weeks after TAC (data not shown). However, expression of HIF-1 
was much higher in the TG heart but lower in the KO heart than that in WT one at 4 
weeks after TAC (Fig. 3a). While expression of p53 was not increased in the TG heart 
until 4 weeks after TAC, but it showed a higher level in the KO heart after TAC as 
compared with WT one (Fig. 3b). These results suggest that HSF1 could regulate the 
expression of HIF-1 and p53 in heart during pressure overload. 
 
HSF1 regulated expression of HIF-1 through p53 during pressure overload 
To further elucidate the roles of HIF-1 and p53 in HSF1-related adaptive hypertrophy 
during pressure overload, we introduced a HIF-1 gene or a small interfere RNA (siRNA) 
of p53 into myocardium of the KO mice and a p53 gene or a siRNA of HIF-1 into 
myocardium of the TG mice, and performed TAC in these mice. Injection of the HIF1 
gene into heart did not affect maladaptive state of the KO mice after TAC, whereas TAC 
could induce an adaptive hypertrophy in the KO mice after downregulation of p53 by the 
siRNA (Fig. 4a-c), indicating that at the deficiency of HSF1, injection of an extrinsic 
HIF-1 gene could not exert roles while inhibition of the intrinsic p53 might function 
during TAC. In the TG mice, however, introducing a p53 gene into myocardium did not 
affect adaptive state after TAC, while TAC could induce a maladaptive hypertrophy after 
downregulation of HIF-1 by the siRNA (Fig. 4d-f), indicating that in 
HSF1-overexpressing heart, effect of an extrinsic p53 gene was abolished but inhibition 
of HIF-1 by a siRNA was not interrupted. These results collectively suggest that 
HSF1-dependent effects on cardiac hypertrophy during TAC are relative to the regulation 
of p53 and HIF-1 and that HSF1 may regulate HIF-1 through p53. 
 
Endothelial cells were involved in HSF1-ralated protection of the heart during 
pressure overload 
Since angiogenesis was significantly involved in the development of cardiac hypertrophy, 
we therefore asked whether HSF1-regulated protection of heart during pressure overload 
was due to the functions of microvascular endothelial cells (MEC). We cultured 
endothelial cells isolated from myocardium of adult WT, TG and KO mice and stretched 
them before implanted into matrigel. The abilities to form tube-like structures were not 
different among the three types of MEC without mechanical stretch (Fig. 5a). However, 
when mechanical stretch was imposed, the microvascular tubes were more formed by the 
MEC of TG mice but less by the MEC of KO mice than those by the MEC of WT mice 
(Fig. 5a). However, mechanical stress-evoked hypertrophic responses were not 
significantly different among the three types of cultured cardiomyocytes (data not shown). 
Also, after mechanical stretch, expression of HIF-1 was significantly increased in MEC 
(Fig. 5b, c) but not in cardiomyocytes of the TG mice (data not shown), while expression 
of p53 was significantly upregulated in the MEC (Fig. 5b, d) but not in cardiomyocytes 
of the KO mice (data not shown). These results indicate that the adaptive or the 
maladaptive cardiac hypertrophy observed in HSF1-TG or -KO mice, respectively, 
during pressure overload is, at least in part, related to the abilities of neovascularization 
by MEC but not to the hypertrophic responses of cardiomyocytes. 
 
miR-378 and mi-R379 were regulators for cardiac HSF1 during pressure overload. 
To explore the reason for the suppression of HSF1 in myocardium after pressure overload, 
we employed a microRNA (miRNA) analysis in hearts of the WT, TG and KO mice after 
TAC for 2 weeks. Microarray showed 190 miRNAs significantly upregulated or 
downregulated in the WT heart after TAC, among which 10 were associated with the 
regulation of HSF1 (data not shown). Furthermore, among the 10 miRNAs, only the 
expression of miR-378 and miR-379 was not changed among the three types of hearts 
without TAC (Fig. 6a). After TAC, however, miR-378 was decreased in hearts of both the 
WT and the KO but increased in the TG heart, while miR-379 was upregulated in hearts 
of both the WT and the KO but downregulated in the heart of TG mice (Fig. 6a). These 
results suggest that miR-378 and miR-379 might be related to the regulation of HSF1 
during TAC and that miR-378 may be positively but miR-379 negatively regulated the 
expression of HSF1 
To confirm the data of miRNA array, we examined the expression of miR-378 and 
miR-379 in hearts of the WT, TG and KO mice after TAC using Northern blot method. 
Consisting with the results of miRNA array, miR-378 was decreased but miR-379 
increased in the hearts of WT and KO mice, whereas miR-378 was increased but miR-379 
decreased in heart of the TG mice (Fig. 6b, left panels and c). We also examined the 
expression of miRNAs in human hearts, and also found that miR-378 was downregulated 
but miR-379 upregulated in the failing heart compared to the heart without failure (Fig. 
6b, right panels). 
 
miR-378 and siRNA of miR-379 benefited the pressure-overloaded hearts 
To test whether overexpression of miR-378 or inhibition of miR-379 could ameliorated a 
maladaptive cardiac hypertrophy, we transfected the miR-378 or a siRNA of miR-379 
into the myocardium of WT mice at 2 weeks after TAC and observed the development of 
cardiac hypertrophy and heart functions for another 2 weeks. At 4 weeks after TAC, the 
mice injected with miR-378 or siRNA of miR-379 showed a preserved cardiac 
hypertrophy and heart functions (Fig 6d), which was similar to those in the HSF1 TG 
mice. Also, cardiac angiogenesis and HSF1 expression was significantly increased in 
myocardium of the miR-378 or siRNA of miR-379-transfected mice compared to those 
without the transfection (Fig. 6d, e). These results strongly suggest that miR-378 and 
miR-379 are regulators for HSF1 in the heart and that upregulation of miR-378 or 
downregulation of miR-379 can ameliorate the maladaptive cardiac hypertrophy during 
pressure overload. 
 
Discussion 
Transition of the adaptive cardiac hypertrophy to a maladaptive one during hypertension 
is an important point to the development of heart failure 1, 2, 4, 9. It is therefore necessary 
to explore a effective method to arrest the transition. In the present study, we found that 
overexpression of HSF1 in the heart preserved adaptive hypertrophy and cardiac function 
through maintenance of cardiac angiogenesis during pressure overload; HSF1 
upregulated HIF-1 through downregulation of p53; miR-378/miR-379 were involved in 
the regulation of HSF1 in pressure-overloaded heart in mice. 
Although pressure overload-induced cardiac hypertrophy usually develops to 
heart failure eventually, exercise-induced cardiac hypertrophy does not 3, 5. We have 
recently reported that the prolonged adaptive state of exercise-induced cardiac 
hypertrophy is regulated by HSF1 and HSPs, and that HSF1-TG mice do not develop to 
maladaptive cardiac hypertrophy under chronic pressure overload 6. In the present study, 
we also showed that under a persistent pressure overload, overexpression of the HSF1 in 
mice heart enhanced cardiac hypertrophy and delayed cardiac dysfunctions, while 
decrease of HSF1 impaired adaptive cardiac hypertrophy and aggravated cardiac 
dysfunctions. However, the mechanism of how HSF1exerts on the heart has been still 
unclear although the protection of cardiomyocytes from death has been speculated 6. We 
recently observed that inhibition of angiogenesis causes transition of an adaptive 
hypertrophy to cardiac dysfunctions during pressure overload 9 and that increases in 
cardiomyocyte death evaluated by a TUNEL method was observed from 2 weeks but not 
at early phase after pressure overload (unpublished data), suggesting that angiogenesis 
may play a role in protection of the heart by HSF1. In our present results, angiogenesis 
was significantly more in the heart of HSF1 TG mice but less in the heart of HSF1 KO 
mice compared to WT heart after TAC. The changes of angiogenesis are paralleled to 
those of cardiac functions. Inhibition of angiogenesis by an inhibitor abolished 
preservation of cardiac adaptation in the HSF1 TG mice, while overexpression of 
angiogenic factors in the heart of HSF1 KO mice improved maladaptive hypertrophy 
under pressure overload. These results collectively show a pivotal role of angiogenesis in 
the beneficial effect of HSF1 on a workloaded heart. 
HIF-1, a key transcription factor for the hypoxic induction of angiogenesis factors, 
can induce adaptive metabolic change as well as VEGF-mediated angiogenesis, which 
lead to the formation of new vessels 11, 12. In the previous study, upregulation of HIF-1 
expression and activation has been indicated to be important for the adaptive mechanism 
of cardiac hypertrophy at early phase during pressure overload 9. In the present study, 
expression of HIF-1 was higher in the TG heart but lower in the KO heart compared to 
the WT one after TAC, suggesting that HSF1 may affect expression of HIF-1. However, 
overexpression of the HIF-1 in the heart lacking HSF1 did not benefit the maladaptive 
hypertrophy after TAC although overexpression of its downstream factors Ang-1 and 
VEGF did improve the cardiac functions in the same type of mice, indicating that there 
might be another mechanism existing in the HSF1 KO heart to suppress the effect of 
HIF-1 but not that of its downstream factors during pressure overload. It has been 
reported that HSF1 can act as a modifier of tumorigenesis through regulation of p53, 
which is required for tumor initiation and maintenance in a variety of cancer models 13. It 
has also been indicated that p53 plays a critical role in the inhibition of adaptive 
upregulation of HIF-1 and angiogenesis during a chronic pressure overload 9, which 
induces transition of cardiac hypertrophy to dysfunctions. In the present study, expression 
of p53 was significantly downregulated in the HSF1 TG heart but significantly 
upregulated in the KO one, while expression of HIF-1 was significantly upregulated in 
the HSF1 TG heart but downregulated in the KO one. Transfection of a siRNA into 
myocardium to knockdown the expression of p53 rather than overexpression of a HIF-1 
gene significantly reversed the maladaptive hypertrophy in the KO mice whereas 
introduction of a siRNA of HIF-1 but not a p53 gene into the TG heart did worse the 
adaptive hypertrophy after TAC. These results collectively indicate that HSF1 exerts 
effects on the cardiac angiogenesis after pressure overload through suppression of p53 
and thereby upregulating HIF-1, which leads to the adaptation maintenance of the 
pressure-overloaded heart. 
It has been indicated that HSF1-regulated protection of heart is due to a direct 
protection of cardiomyocytes from death 6, 10, 14. Sakamoto et al. indicated that the 
number of cardiomyocyte apoptosis was significantly less in the heart of HSF1 TG mice 
compared with that of WT mice after pressure overload and that expression of 
transforming growth factor was markedly increased in the heart after pressure overload 
but was significantly prevented by overexpression of HSF1 6. It is therefore thought that 
HSF1 prevents cardiomyocyte death by antagonizing the proinflammatory pathways, 
thereby preventing the transition from adaptive to maladaptive hypertrophy. Since 
angiogenesis also accounts for the development of cardiac hypertrophy 9, we therefore 
cultured MEC of hearts. Expression of HIF-1 and that of p53 were significantly observed 
in the MEC, but they were nearly undetectable in cardiomyocytes from the HSF1 TG and 
the KO mice even after mechanical stretch (unpublished data). Meanwhile, the 
vasculature formation was more significantly by the MEC of TG mice but less by the 
MEC of KO mice, whereas hypertrophic responses induced by mechanical stretch were 
similar between the two types of cardiomyocytes. These results collectively indicate that 
HSF1-associated long-term maintenance of adaptive cardiac hypertrophy is regulated by 
the MEC rather than by cardiomyocytes. These results also suggest a proper target cell 
for the treatment of heart failure. 
It remains unclear how HSF1 is downregulated under sustained pressure overload. 
Extracellular signal-regulated protein kinase (ERK) may increase HSF1 activity and 
participate in the activation of HSF1 in exercise-induced hypertrophy 6. However, ERK 
has usually been known to be involved in abnormal growth of cells including 
pathological cardiac hypertrophy 15. miRNAs are naturally existing, small, noncoding 
RNA molecules that downregulate posttranscriptional gene expression 16. Their 
expression pattern and function in the heart has been recently demonstrated 17-21. It has 
been shown that miRNAs play essential regulatory roles in the development of cardiac 
hypertrophy and that downregulation of miR-1 is necessary for the relief of 
growth-related target genes from its repressive influence and induction of hypertrophy 
17-19. It has also been reported that miR-133, which belongs to the same transcriptional 
unit to miR-1 and is decreased in mouse and human models of cardiac hypertrophy, has a 
critical role in determining cardiomyocyte hypertrophy 20. However, these miRNAs are 
muscle relative that do not regulate cardiac angiogenesis. To explore the miRNAs 
targeting HSF1and angiogenesis in the heart, we performed a miRNA array of hearts in 
the HSF1 TG, KO and WT mice after TAC for 2 weeks when transition of the adaptive 
hypertrophy to the maladaptive one initiates naturally 9. Among the significantly changed 
miRs relative to HSF1, miR-378 was lower in the WT and KO but higher in the TG heart, 
whereas miR-379 was higher in the WT and KO but lower in the TG heart, which is 
consistent with or contrast to the transcription levels of HSF1 in the heart, respectively. 
miR-378 has been reported to enhance cell survival, tumor growth, and angiogenesis 
through repression of the expression of two tumor suppressors, Sufu and Fus-1 22.  
miR-379 has been indicated to play an important role in neurogenesis in the placental 
mammals 23. However, the role of them in the regulation of cardiovascular diseases has 
not yet been reported. Here, introduction of the miR-378 or siRNA of miR-379 into 
myocardium of the WT mice resulted in an upregulation of HSF1 and angiogenesis, and a 
preservation of cardiac adaptation. These results indicate that miR-378 and miR-379 are 
also regulators for expression of HSF1 during mechanical stresses and that they may be 
as target molecules to interrupt the transition of an adaptive cardiac hypertrophy to a 
maladaptive one. Future study will focus on how miR-378 and miR-379 regulate HSF1 
and whether there is a relationship between the two miRs in the regulation of HSF1. 
In summary, we observed that overexpression of the HSF1 in heart of mice 
induced an improvement of angiogenesis through downregulation of p53 and subsequent 
upregulation of HIF-1, leading to a preservation of adaptive hypertrophy and cardiac 
functions and that miR-378 and miR-379 were involved in the regulation of HSF1 
expression in heart during a persistent pressure overload. Although further studies are 
required, upregulation of HSF1 by promotion of miR-378 and/or inhibition of miR-379 in 
the heart may be a novel therapeutic strategy for preventing the transition from adaptive 
cardiac hypertrophy to heart failure. 
Methods 
Mice. Generation of the HSF1 TG and KO mice has been previously described 24, 25. 
Twelve-week-old male TG, KO and WT mice were used. There were no significant 
differences in BW, HW, HW to BW ratio (HW/BW), BP and HR among three types of 
mice at basal condition. All animal experimental protocols were approved by the Animal 
Care and Use Committee of Fudan University, and in compliance with guidelines for the 
Care and Use of Laboratory Animals published by the National Academy Press (NIH 
Publication No. 85-23, revised 1996). 
 
Pressure-overload model. Strong pressure overload was imposed on the heart of mice 
by TAC operation as described previously 9. In brief, mice were anesthetized by 
intraperitoneal injection of a cocktail of ketamine HCl (100 mg/kg) and xylazine (5 
mg/kg) and artificially ventilated using a respirator. The transverse aorta was constricted 
together with a blunted 27-gauge needle, which was pulled out later. Haemodynamic 
measurements were taken by inserting a micronanometer catheter (Millar 1.4F, SPR 671, 
Millar Instruments) from the right common carotid artery into aorta and then LV. The 
transducer was connected to Power Laboratory system (AD Instruments, Castle Hill, 
Australia), and BP, HR, and LVEDP were measured. 
 
Injection of the adenovirus vectors into myocardium of mice. Constructions of 
adenovirus vectors encoding HIF-1, VEGF, Ang-1and p53 were as previously described 9. 
Adenovirus vectors encoding miR-378 were generated by PCR from mouse genomic 
DNA fragments (Invitrogen). siRNA of p53 and HIF-1 and their scramble RNA were 
purchased from SantaCruz Biotechnology, Inc. siRNA of miR-379 was purchases from 
Genepharma, Inc. (Shanghai, China). siRNAs were inserted into adenovirus vectors 
(Invitrogen). Infusion of the relative adenovirus vectors into myocardium through 
coronary artery was performed in some of WT, TG and KO mice 2 days before TAC as 
reported previously 9. Efficacy of the transfection into myocardial evaluated by an X-gal 
staining of Ad. LacZ vector was ~50% (data not shown). Injection of the siRNA induced 
a significant knockdown (> 50%) of the relative mRNA evaluated by the RT-PCR in 
myocardium (data not shown). 
 
miRNA microarrays. Adult WT, TG and KO mice were subjected to sham or TAC 
operation. Two weeks later, the animals in sham groups with normal BP (100~120 mmHg) 
and those in TAC groups with significant elevation of BP (40~50 mmHg) were enclosed. 
Low-molecular-weight RNA was isolated from cardiac tissue by using the mirVana 
miRNA Isolation Kit (Ambion, Austin, TX). RNA from three animals in each group was 
pooled and used for miRNA expression analysis by using the miRMAX microarray. A 
total of 186 miRNAs examined showed comparable relative expression at baseline. The 
miRNAs without changes among the WT, HSF-1 TG and the KO hearts subjected to 
sham operation were selected for comparison. Differentially regulated miRNAs were 
defined as those with either < 0.5- or > 1.5-fold changes in expression compared the 
expression levels of sham hearts with TAC ones. 
 
Northern blotting. Total RNA was extracted from heart tissues using TRIzol reagent 
according to the protocol of the manufacturer (Invitrogen). To aid analysis of miRNA, 
polyethylene glycol was applied to remove large-sized RNA. Nothern blot analysis was 
performed as described elsewhere 26. The microRNA Detection Probes of miR-378 and 
miR-379 were obtained from miRCURY LNA™ . The probes were 5’-end labeled with 
biotin using miRNA probe and marker kit and used for hybridization. 
 
Human heart tisssues. We obtained the human heart tissues from the Zhongshan 
Hospital, Fudan University under the procedures approved by the Ethnic Committee for 
Use of Human Samples of the Fudan University. The LV tissues were from two rejected 
hearts of healthy persons during heart transplantation and from two explanted hearts of 
patients with end stage of heart failure. 
 
Echocardiography. Transthoracic echocardiography was performed using an animal 
specific instrument (VisualSonics Vevo770, VisualSonics Inc. Canada) 6, 9. Mice were 
weakly anesthetized and M-mode images of the LV were recorded when the mice 
partially recovered from anesthesia. All measurements were averaged for three 
consecutive cardiac cycles and were carried out by three experienced technicians who 
were unaware of the identities of the respective experimental groups. 
 
Culture of cardiac myocytes and microvascular endothelial cells of mice. Cardiac 
myocytes and MEC were prepared from ventricles of 1-day-old neonatal WT, TG and 
KO mice. The cells were cultured in silicone dishes at a density of 1X105 cells/cm2 in 
Dullbecco modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS) for CM and in 100-mm dishes at a density of 5X104 cells/cm2 in DMEM 
supplemented with 20% FBS for MEC to grow to subconfluence as described elsewhere. 
The 2~3 passages of MEC were used for vascular formation experiments 
 
Microvascular formation experiment. MEC were characterized by the 
immunocytochemistry staining with an anti vWF antibody and showed a purity of more 
than 95%. After 2-3 passages of culture, the MEC were resuspensed in 2% FBS-DMEM, 
implanted onto the matrigel (BD) in 24-well plate in a density of 5x104 cells/well and 
grown for 18 hours. Some of MEC were subjected to a mechanical stretch for 30 min 
before implantation onto the matrigel. The capillary formation was observed under a 
microscope and quantified by calculating the number of tube-like structures in whole 
well. 
 
Histological analysis. Heart tissues were fixed in 10% formalin and embedded in 
paraffin or frozen in cryomolds, sectioned at 4 μm thickness and stained with 
hematoxylin and eosin (H-E) for histological examination, Masson trichrome for fibrosis 
and anti vWF for vascular endothelial cells, respectively. Digital photographs were taken 
at magnification x25, x100, x400, x1000, respectively. For measurement, five random 
high-power fields from each section were chosen and quantified in a blinded manner. The 
extent of fibrosis and the densities of vasculatures were measured in 5 sections from each 
heart and the value was expressed as the ration of Masson trichrome stained area to total 
LV wall or as the number of blood vessels/mm2, respectively. 
 
Reverse transcription-polymerase chain reaction (RT-PCR) analysis. Total RNA was 
isolated from the heart tissues or cells using TRIzol reagent (15596-018, Gibco BRL). 
The expression of the relative mRNA levels was evaluated using RT-PCR. The PCR 
products were subject to electrophoresis on 1.5% agarose gels, scanned, and 
semi-quantitated using Image-Quant software (Kodak 1D V3.53; Kodak, New Haven). 
 
Statistics. Data are presented as mean ± S.E.M. Multiple group comparison was 
performed by one-way ANOVA followed by LSD procedure for comparison of means. 
Comparison between 2 groups under identical conditions was performed by the 2-tailed 
Student’t test. A value of p < 0.05 was considered statistically significant. 
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Figure Legends 
Figure 1: Cardiac hypertrophy and functions after TAC.  (a-c) TAC was induced in 
adult male WT (a), HSF1-TG (b) and KO (c) mice, and echocardiography (ECHO), 
cardiac catheterization, hematoxylin-eosin staining (H-E) and masson-trichrome staining 
(MS) were performed 2 (2W) and 4 weeks (4W) later. Representative photographs are 
shown (scale bars: 200 μm). There were no differences in LV wall thickness, LV cavity 
and myocardial fibrosis among the sham-operated (Sham) three types of mice. TAC for 2 
weeks induced a significant cardiac hypertrophy including the increase in LV wall 
thickness, decrease of LV cavity and increase in myocardial fibrosis in WT mice. 
However, LV wall was thicker, cavity was smaller and fibrosis was less in the TG mice 
whereas LV wall was thinner, cavity was larger, and fibrosis was more in the KO mice 
than in WT mice. At 4 weeks, LV wall thickness was decreased, cavity was enlarged and 
myocardial fibrosis was increased compared to those at 2 weeks in WT mice. All these 
changes were less in TG mice but more in the KO mice. (d) Echocardiographic analyses 
for left ventricular ejection fraction (%LVEF) and end-diastolic LV inner diameter 
(LVIDd).  Data are expressed as mean ± S.E.M. of five mice (n=5). * p < 0.05 vs Sham; 
# p < 0.05 vs 4W in WT mice. 
 
Figure 2: Effects of angiogenesis on cardiac hypertrophy. (a) Microvasculature 
densities. WT, TG and KO mice were subjected to TAC for 4 weeks. Heart sections were 
immunohistochemically stained with anti vWF antibodies. Representative photographs 
are shown (original magnification x1000). Sham, sham-operated WT mice. Brown color 
indicates vWF-positive capillaries. vWF-positive vasculatures were calculated as the 
numbers per mm2 area in LV wall. Data are expressed as mean ± S.E.M. of five hearts 
(n=5). * p < 0.05 vs Sham; # p < 0.05 vs WT with TAC. (b) Effects of TNP-470 on 
cardiac hypertrophy in the TG mice. TG mice were treated with TNP-470 (TNP) or 
vehicle 9, and subjected to TAC for 4 weeks. Heart sections were stained with H-E and 
representative photographs from 5 hearts were shown (scale bars: 2 mm). Sham, 
sham-operated TG mice; TAC, vehicle-treated TG mice with TAC; TNP-TAC, 
TNP-treated TG mice with TAC. (c) Effects of overexpression of angiopoietin1 (Ang1) 
and VEGF in myocardium on cardiac hypertrophy in the KO mice. Adenovirus vectors 
encoding Ang1 and VEGF were injected into myocardium of the KO mice, and the mice 
were subjected to TAC for 4 weeks. Heart sections were stained with H-E and 
representative photographs from 5 hearts were shown (scale bars: 2 mm). Sham, 
sham-operated KO mice; TAC, vector-injected KO mice with TAC; VEGF+Ang1-TAC, 
VEGF and Ang1 genes-injected mice with TAC. 
 
Figure 3: Expression of HIF-1 and p53 in the heart after TAC. The WT, TG and KO 
mice were subjected to TAC for 4 weeks. mRNA was extracted from the LV tissues and 
subjected to a RT-PCR analyses for HIF-1 (a) and p53 (b) expression. GAPDH was used 
as a loading control. Upper, representitive photographs. Expression of HIF-1 and p53 
were quantified as % of GAPDH expression. Data are expressed as mean ± S.E.M. from 
five mice (n=5). * p < 0.05 vs sham-operated WT mice; # p < 0.05 vs WT mice with 
TAC. 
 
Figure 4: Effects of HIF-1 and p53 on cardiac hypertrophy after TAC. Adenovirus 
vectors encoding HIF-1, p53 and siRNA of HIF-1 (HIF-1 siRNA) or p53 (p53 siRNA), or 
empty vectors (Vector) were injected into hearts of the KO (a-c) and TG (d-f) mice, and 
the mice were subjected to TAC or sham for 4 weeks. Echocardiography (a and d, upper) 
and H-E staining (a and d, bottom) were used to evaluate cardiac hypertrophy and 
functions. (a) Representative photographs from the KO mice (scale bars: 2 mm). (b and c) 
Echocardiographic parameters (LVIDd and %LVEF) were quantitated as mean ± S.E.M. 
of five KO mice. * p < 0.05 vs sham; # p < 0.05 vs TAC-operated mice with vector 
injection. (d) Representative photographs of the TG mice. (e and f) Quantification of 
LVIDd and %LVEF. Data are expressed as mean ± S.E.M. of five TG mice. # p < 0.05 vs 
TAC-operated mice with vector injection. 
 
Figure 5: Formation of vasculatures by cardiac endothelial cells of microvessels 
(MEC). MEC were isolated from LV of the WT, TG and KO mice. Vasculature formation 
experiments were performed as described in Methods. (a) Representative photograms of 
vessel-like tubes from five independent experiments were shown. CT, control, MEC 
without stimulation; MS, MEC with mechanical stretch stimulation. Total vessels were 
counted in whole dish. (b) Representative RT-PCR analyses for HIF-1 and p53 
expression of the MEC as in a. GAPGH was used as loading control. Expression of 
HIF-1 and p53 was quantified as % of GAPDH expression. Data are expressed as mean ± 
S.E.M. of five independent experiments (n=5). * p < 0.05 vs controls; # p < 0.05 vs MEC 
from the WT mice stimulated by mechanical stretch. 
 
Figure 6: Analysis of miR-378 and miR-379 in the pressure overloaded hearts. 
Low-molecular-weight or total RNA was extracted from hearts of the WT, TG and KO 
mice subjected to sham or TAC operation for 2 weeks. (a) miRNA array expression data. 
Representative photogram of microarray (left) was shown. The expression levels of 
miR-378 and miR-379 were quantified as the fold of expressions in the heart of 
sham-operated WT mice. (b) Northern blot analyses. Expression of miR-378 and miR-379 
was examined using total RNA of heart tissues from mice as in a (left) and human (right). 
tRNA was used as loading control. Representative photograms from three independent 
experiments are shown. NH, heart of human without heart failure; FH, heart of human 
with heart failure. (c) Quantitation of Northern blotting. Expression levels were 
calculated as the fold of expressions in the heart of sham-operated WT mice. Data are 
expressed as mean ± S.E.M. from three independent experiments (n=3). * p < 0.05 vs WT 
mice with sham operation. (d) Effects of miR-378 and miR-379 on cardiac hypertrophy 
and functions. Adult WT mice were subjected to TAC. Two weeks later, the miR-378 
(378), siRNA of miR-379 (si379) or empty vector (Vector) were infused into myocardium 
of the mice. Representative echocardiography (upper), H-E staining (middle) and 
innunohistochemical staining with anti vWF antibodies (bottom) performed at 4 weeks 
after TAC were shown (scale bars: 2 mm). Echocardiographic parameters (LVIDd 
and %LVEF) and vWF-positive capillaries were quantitated as mean ± S.E.M. of five 
hearts. * p < 0.05 vs sham with empty vector injection; # p < 0.05 vs TAC-operated mice 
with empty vector injection. (e) Expression of HSF1. Representative RT-PCR (upper) and 
Western blot (bottom) analyses for HSF1 in heart of mice as in d. GAPDH and α-actin 
were used as loading controls for RT-PCR and Western blotting, respectively. 






